DDR2 mutation serves as an inclusion eligibility criterion in a clinical trial targeting MGCD516, a receptor tyrosine kinase inhibitor, for patients with NSCLC, or metastatic tumors (https://www.mycancergenome.org). The gene discussed is DDR2; the disease is metastatic neoplasm.